Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

After initial TNFi, RA patients stay on subsequent nonTNFi drug longer

Publish date:: June 23, 2020

Key clinical point: RA patients who switched from a TNF inhibitor (TNFi) as their first biologic to a non-TNFi were more likely to continue therapy, but those who cycled to a second TNFi incurred lower overall costs.

Major finding: Among RA patients who failed initial TNFi therapy, 63.5% cycled to a second TNFi and 36.5% switched to a non-TNFi drug,

Study details: The data come from a database review of 10,442 adults with RA.

Disclosures: The study was supported in part by an Investigator Award from the Rheumatology Research Foundation to Dr. Matusevich. One author is an employee of Optum, and one author disclosed financial relationships with multiple pharmaceutical companies.

Citation:

Matusevich ARK et al. Arthritis Care Res. 2020 June 17. doi: 10.1002/acr.24358.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Rheumatoid Arthritis

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Tocilizumab, methotrexate combo equals tocilizumab alone for preventing progression,

Biomarker-based prognostic score identifies cardiovascular risk in RA,

Early life exposure to famine raises risk of RA in adulthood,